Abcam and TTP Labtech collaborate to develop sol-R reagent kits
Assay-ready kits will incorporate fully-validated, industry-leading recombinant antibody technology for high throughput research.
TTP Labtech and Abcam has announced a collaboration to further develop reagent kits for the quantification of secreted proteins in multiplexed screening assays.
Following the successful launch last year of sol-R coded beads, TTP Labtech is working with Abcam to meet customer needs by developing assay ready kits which enable researchers to deliver data driven decisions faster and with confidence. The sol-R reagent kits will offer Abcam’s highly validated and quality assured antibodies including recombinant antibody pairs, combined with the reliability of sol-R coded beads and mirrorball fluorescence cytometry technology from TTP Labtech for sample analysis.
Joby Jenkins, director – product strategy, TTP Labtech, commented: “Our sol-R coded beads are designed for secreted protein quantification in multiplexed no-wash immunoassay screens. Working with Abcam on the development of the sol-R reagent kits enables us to combine their advanced antibody technology and reagent expertise with our sol-R bead technology to provide convenient off-the-shelf kits. Since the kits are validated on TTP Labtech’s mirrorball plate-based fluorescent cytometer, repeated wash steps associated with traditional sandwich ELISA’s are no longer necessary, thereby significantly reducing assay times, while delivering data integrity.”
John Baker, Senior Vice President Portfolio and Business Development, at Abcam, said: “The integration of Abcam’s high quality antibody technology with TTP Labtech’s sol-R Reagents will deliver reproducibility, quality and efficiency to life science researchers, accelerating their research. The new kits have been designed for researchers carrying out high-throughput immunoassays including drug discovery in biotech, pharma and contract research organisations.”
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance